Subscribe to Search results

BPL started development work on a heat-treated 'Hepatitis-Safe' Factor 8 product.

Published on:

FDA licensed Hyland's dry heat-treated product.

Published on:

FDA licensed Armour's heat-treated product, followed by Alpha's and Cutter's products in February 1984.

Published on:

Haemophilia centres at Sheffield, St Thomas', Middlesex and Margate started to use heat-treated concentrates.

Published on:

BPL started intensive development of what would become 8Y.

Published on:

Reported at symposium in Groningen that heat treatment at 68°C for 24 hours inactivated HIV; PFC was heating its Factor 8 stocks; CBLA announced plans to heat all BPL Factor 8 by April 1985.

Published on:

PFC issued heat-treated Factor 8 for routine use.

Published on:

There was a meeting at Elstree of reference centre directors and others to devise treatment recommendations.

Published on:

Commercial heat-treated concentrates were licensed in UK.

Published on:

BPL released first batches of 8Y for clinical trial.

Published on:

All Factor 8 issued by BPL heat-treated by this date.

Published on:

Only 8Y was issued after this date.

Published on:

BPL and PFL heat-treated F9 became routinely available.

Published on:

Armour withdrew heat-treated Factorate following seroconversions.

Published on:

PFC issued Z8, the equivalent of 8Y free from hepatitis as well as HIV.

Published on:

First formal meeting of haemophilia centre directors took place.

Published on:

Dr Craske reported to the UK Haemophilia Centre Directors ("UKHCDO") hepatitis outbreak in Bournemouth linked to commercial Factor 8.

Published on:

Glasgow symposium considered liver disease in haemophilia.

Published on:

US Centers for Disease Control reported three confirmed cases of people with haemophilia who had developed AIDS.

Published on:

UKHCDO meeting referred to "remote possibility" that commercial blood products were the cause of AIDS in people with haemophilia in the US.

Published on: